NTLA — INTELLIA THERAPEUTICS Share News
0.000.00%
Last trade - 00:00- $1.56bn
- $1.13bn
- $67.67m
U.S. STOCKS ON THE MOVE-ANI Pharmaceuticals, Wendy's, nLIGHT
U.S. STOCKS ON THE MOVE-Tesla, gold and silver miners
Intellia falls after US FDA halts key heart disease trials following patient death
U.S. RESEARCH ROUNDUP- Blackline, Carmax, Expedia
Intellia Q3 net loss narrows
Brief: Intellia Therapeutics Q3 Net Income USD -101.324 Million
U.S. STOCKS ON THE MOVE-Fiserv, CMS Energy, Moderna
U.S. STOCKS ON THE MOVE-Wolfspeed, Carvana, Metsera
Intellia falls as FDA places clinical hold on its gene therapy trials
US FDA places clinical hold on Intellia's gene-editing treatment trials; shares fall (updated)
US FDA places clinical hold on Intellia's two gene-editing treatment trials
U.S. RESEARCH ROUNDUP-ATI, GoDaddy, Lyft
U.S. RESEARCH ROUNDUP- BCB Bancorp, Cadence Design Systems, Intellia Therapeutics
U.S. STOCKS ON THE MOVE-PepGen, Turbo Energy, Qualcomm
Intellia plunges after co pauses late-stage trials of gene-editing treatment
Brief: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran
Intellia slumps after co pauses late-stage trials of gene-editing treatment
Intellia pauses late-stage trials of gene-editing treatment after serious liver event (updated)
Intellia pauses late-stage trials of gene-editing treatment after serious liver event